The last three decades have witnessed an epidemic rise in the number of people with diabetes, especially type 2 diabetes, and particularly in developing countries, where more than 80% of the people with diabetes live. The rise of type 2 diabetes in South Asia is estimated to be more than 150% between 2000 and 2035. Although aging, urbanization, and associated lifestyle changes are the major determinants for the rapid increase, an adverse intrauterine environment and the resulting epigenetic changes could also contribute in many developing countries. The International Diabetes Federation estimated that there were 382 million people with diabetes in 2013, a number surpassing its earlier predictions. More than 60% of the people with diabetes live in Asia, with almost one-half in China and India combined. The Western Pacific, the world’s most populous region, has more than 138.2 million people with diabetes, and the number may rise to 201.8 million by 2035. The scenario poses huge social and economic problems to most nations in the region and could impede national and, indeed, global development. More action is required to understand the drivers of the epidemic to provide a rationale for prevention strategies to address the rising global public health “tsunami.” Unless drastic steps are taken through national prevention programs to curb the escalating trends in all of the countries, the social, economic, and health care challenges are likely to be insurmountable.

Diabetes is now a disease of major concern both globally and regionally and is a leading cause of death in most countries (1). In 2013, the International Diabetes Federation (IDF) estimated that ∼382 million people had diabetes worldwide, and by 2035, this was predicted to rise to 592 million. Eighty percent live in low- and middle-income countries, and of the total, more than 60% live in Asia, with almost one-third in China (2). Major increases in the prevalence of diabetes have occurred in developing countries due to rapid and ongoing socioeconomic transition and will likely lead to further rises (2). The prevalence of both type 1 and type 2 diabetes (T2DM) has increased significantly during recent decades. T2DM, being much more common (2), has been the main driver for the increase in global diabetes prevalence and, therefore, will be the focus of this review.

It should be noted that with regard to diabetes prevalence, only broad comparisons can be made among studies on which national and global estimates by the IDF are based. This is because there are marked differences in age-groups, survey methodologies, diagnostic criteria, and other aspects of these studies in the various countries in Asia and the Pacific. Despite this, almost all developing countries in the Western Pacific region (WPR) (3) and also in South Asia (46) have shown escalating rates.

The WPR is the world’s most populous World Health Organization (WHO) region, comprising 39 heterogeneous countries and territories, with populations ranging from more than 1 billion people in China to 10,000 in small Pacific Island nations like Tuvalu. The region has undergone rapid changes developmentally, socioeconomically, politically, and culturally during the last few decades (3).

The increasing prevalence of diabetes can be attributed to a multitude of interrelated factors, including rapid industrialization and urbanization and the ensuing changes in lifestyle factors (4,6). The effect of the intrauterine environment and the resulting epigenetic changes may also convey increased risk of T2DM and other chronic diseases in adult life (1,7). Epigenetic changes can be transmitted to future generations, thus becoming intergenerational. The risk factors for T2DM are summarized in Table 1 and are detailed below. Interestingly, the propensity of these risk factors to cause diabetes appears higher among the populations in South Asia and in the WPR compared with Western populations, and this is discussed in a later section.

Table 1

Plausible etiological factors responsible for the increased propensity to develop T2DM

Genetic and acquired factors
 Genetic factors (familial aggregations) 
 Ethnic susceptibility 
 Adverse gene–environment interaction (i.e., epigenetics, metabolic maladaptations) 
 Lower threshold for diabetogenic risk factors (i.e., age, BMI, central adiposity) 
 Low muscle mass 
 Increased insulin resistance 
 Decreased β-cell compensation   disproportionate to insulin insensitivity 
 Presence of metabolic obesity 
 Increased inflammatory response 
Environmental risk factors 
 Urbanization and modernization 
 Globalization and industrialization 
 Unhealthy behavioral habits (sedentary  lifestyle, consumption of energy-  dense food, smoking, tobacco chewing,   and excessive alcohol consumption) 
 Sleep disturbances 
 Psychological stress 
Societal factors 
 Cultural and religious taboos 
 Psychosocial factors 
 Lack of universal health coverage 
Genetic and acquired factors
 Genetic factors (familial aggregations) 
 Ethnic susceptibility 
 Adverse gene–environment interaction (i.e., epigenetics, metabolic maladaptations) 
 Lower threshold for diabetogenic risk factors (i.e., age, BMI, central adiposity) 
 Low muscle mass 
 Increased insulin resistance 
 Decreased β-cell compensation   disproportionate to insulin insensitivity 
 Presence of metabolic obesity 
 Increased inflammatory response 
Environmental risk factors 
 Urbanization and modernization 
 Globalization and industrialization 
 Unhealthy behavioral habits (sedentary  lifestyle, consumption of energy-  dense food, smoking, tobacco chewing,   and excessive alcohol consumption) 
 Sleep disturbances 
 Psychological stress 
Societal factors 
 Cultural and religious taboos 
 Psychosocial factors 
 Lack of universal health coverage 

T2DM is increasingly present in even children and adolescents (1,35), and the increase in gestational diabetes mellitus (GDM) poses new challenges such as higher risk of diabetes among women and long-term consequences for the offspring (2,6,8,9). Prediabetes prevalence is also higher than that of diabetes in many of the WPR countries (10). T2DM is the focus of this review, which aims to address the major ethnic, demographic, anthropometric, socioeconomic, genetic, and epigenetic factors that are likely to be responsible for the dramatic rise in T2DM. We describe the epidemiological scenario in Asia and in the Pacific. For the purpose of this review, the WPR refers to East Asia, Southeast Asia, Australia, New Zealand, and the Pacific Islands; South Asia refers to Afghanistan, Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, Pakistan, and Sri Lanka (Fig. 1). Many of the nations in these regions do not have national data, so they have not been discussed in detail in this review.

Figure 1

Map shows the Western Pacific and South Asian regions.

Figure 1

Map shows the Western Pacific and South Asian regions.

Close modal

It should be noted that much of the diabetes prevalence data discussed in this review come from IDF estimates (10). These have significant limitations, in that for countries without available local data, estimates are based on modeling using pooled estimates from countries that might be seen to be similar in geography, ethnicity, and economic development. Similarly, numerous country data are based on WHO STEPwise approach to Surveillance (STEPS) studies (11). These are not necessarily comparable with each other owing to methodological differences. These limitations must be considered when examining the data.

Impaired fasting glucose and impaired glucose tolerance (IGT) are high-risk conditions for diabetes and cardiovascular disease (12). China and most of the other countries in WPR have a high prevalence of IGT (3). This is true of many countries in Asia (13). However, many countries use only fasting plasma glucose (FPG) in epidemiological studies and therefore do not have data on IGT. The use of FPG underestimates the true level of diabetes and prediabetes compared with the oral glucose tolerance test (OGTT).

We searched PubMed and Google search using key words “diabetes in Western Pacific Region,” “diabetes in South Asia,” diabetes in individual countries of these regions, “risk factors for T2DM in Western Pacific population,” “risk factors for T2DM in South Asians,” “gestational diabetes among Asian population,” and “prevention of diabetes.” Published reports by the IDF, the WHO, and the American Diabetes Association on the above topics were used. We selected the relevant articles and reviews from peer-reviewed journals identified by the search for preparing the review.

WPR

Today, the nations in the WPR region are highly heterogeneous in economic profile, varying from the high per capita gross domestic product in countries such as Singapore to low gross domestic product in the poorest nations. Developed countries in WPR, such as Australia and New Zealand, have a much lower prevalence of diabetes compared with some developing countries and also the Pacific Islands (14).The IDF estimated that in the WPR in 2013, there were 138 million people with diabetes, 36% of the global total (10). The biggest contribution to this number is China, with 113.9 million adults with diabetes and 493.4 million with prediabetes (15). Some small Pacific Islands, such as Tokelau, according to the IDF estimates and the WHO STEPS studies (11), have a very high diabetes prevalence (Table 2). As mentioned earlier, these are not necessarily comparable with each other owing to methodological differences between and within countries. This point is highlighted in Cambodia by a 2005 report (16) showing that T2DM has emerged at rates similar to those in developed nations such as Australia; yet, a subsequent STEPS modeling study showed that Cambodia had the lowest prevalence in the WPR (10).

Table 2

Prevalence of diabetes in the WPR, with temporal changes shown wherever available*

CountryYear (Ref)Sample size (n)CharacteristicsDiagnostic criteriaDiabetes (%)
American Samoa 2004 (142,072 WHO STEPS; stratified cluster sampling; age: 25–64 years Capillary FPG ≥6.1 mmol/L 47.3 
Australia 2011–2012 (20) NR Age: ≥18 years HbA1c ≥6.5% (≥47.5 mmol/mol) 5.4 
Brunei Darussalam 2003 (21) NR Population-based data from integrated health screening system from medical case records; age: NR Capillary FPG ≥6.1 mmol/L or known diabetes 5.4 
2010 (21) NR Age: ≥20 years Capillary FPG ≥6.1 mmol/L or known diabetes 12.5 
Cambodia 2004 (162,246 Cross-sectional; two communities: rural and semiurban; age: ≥25 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L Rural: 5.0 Suburban: 11.0 
2011 (24) 5,123 WHO STEPS; multistage cluster method (180 clusters); age: 25–65 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L Total: 2.9 (95% CI 2.3–3.4) 
Rural: 2.3 (95% CI 1.7–2.9) 
Urban: 5.6 (95% CI 4.0–7.2) 
China 2001 (25) 15,838 Nationally representative stratified sampling; age: 35–74 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 5.5 
2010 (15) 98,658 Complex, multistage, probability sampling design; age: ≥18 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 11.6 
China, Hong Kong SAR 1990 (221,513 Participants from a public utility company and a regional hospital; age: ≥30 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 4.5 
2007–2010 (233,376 Hong Kong professional driver community project; age: 18–70 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 8.1 
Cook Islands 1980 (141,102 Population-based study; age: ≥20 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 6.8 
2003 (142,036 WHO STEPS; stratified samples; age: NR Capillary FPG ≥6.1 mmol/L or on medication 23.6 
Federated States of Micronesia 1994 (142,188 Population-based study in Kosrae population; age: 20–85 years FPG ≥7.0 mmol/L 12.0 
2002 (141,638 WHO STEPS; population-based cross-sectional study; age: 25–64 years FPG ≥7.0 mmol/L 32.1 
Fiji 2002 (142,277 Population-based multistage sampling in 30 clusters; age: 15–64 years Capillary FPG ≥6.1 mmol/L or on medication; HbA1c ≥6.5% (≥47.5 mmol/mol) or known to have diabetes 16.0 
2009 (141,353 WHO STEPS; population-based study; age: ≥40 years 44.8 
French Polynesia 2010 (143,469 WHO STEPS; population-based multistage sampling; age: 18–64 years Capillary FPG ≥6.1 mmol/L or on medication 7.3 
Indonesia 1997 (18941 Population-based study of government and retired individuals; age: NR FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 5.4 
2009 (1924,417 Samples from 13 urban provinces; age: ≥15 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 5.7 
Japan 1997 (17National Age: ≥20 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L M:F 9.9:7.1 
2007 (17National Age: ≥20 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L M:F 15.3:7.3 
Kiribati 1983 (142,938 Population-based survey; age: ≥20 years; South Tarawa and the four outer islands; age: 15–64 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L Urban: M:F 9.6:8.7 
Rural: M:F 3.0:3.3 
2004–2006 (141,146 WHO STEPS; population- based multistage sampling; age: 18–64 years FPG ≥7.0 mmol/L 28.1 
Malaysia 2006 (2634,539 Malaysian National Health Morbidity Survey (NHMS) III; age: ≥18 years FPG ≥7.1 mmol/L or known to have diabetes 11.6 
2013 (264,341 Two-stage stratified sampling design; age: ≥18 years HbA1c ≥6.5%, FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 22.9 
Marshall Islands 2002 (14994 WHO STEPS; population-based; age: 15–64 years FPG ≥7.0 mmol/L 19.6 
Mongolia 2005 (273,411 WHO STEPS; population-based; age: 15–64 years Capillary FBG ≥6.1 mmol/L or on medication 8.2 
2009 (275,368 WHO STEPS; population-based; age: 15–64 years Capillary FBG ≥6.1 mmol/L or on medication 6.5 
Nauru 1987 (11,201 Population-based data; age: ≥20 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 24.0 
2004 (14883 Systematic random sample design; age: 15–64 years FPG ≥7.0 mmol/L or on medication 16.2 (age 15–24 years) 
22.7 (age 25–64 years) 
New Zealand 2002–2003 (2812,929 Stratified cluster sampling; age: ≥15 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 8.1 
2008–2009 (284,721 Age: ≥15 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 7.0 
Niue 1980 (11,128 Population-based survey; age: ≥20 years FPG ≥7.8 mmol/L 7.2 
2012 (14863 WHO STEPS; population-based; age: ≥15 years Capillary FBG ≥6.1 mmol/L or on medication 38.4 
Papua New Guinea 1991 (14497 Population-based cluster; age: ≥25 years Random blood glucose ≥8 mmol/L or known diabetes Urban: 30.3 
Rural: Wanigela: 11.7 
Kalo: 1.6 
2008 (142,944 WHO STEPS; population-based survey; age: 15–64 years Capillary FBG ≥6.1 mmol/L or on medication 14.4 
Republic of Korea 2005 (294,628 KNHANES; age: ≥30 years FPG ≥7.0 mmol/L or/and history of diabetes 9.1 
2007–2009 (2913,512 Age: ≥30 years FPG ≥7.0 mmol/L 9.9 
2011–2012 (30) 14,330 National Health Survey; age: ≥30 years FPG ≥7.0 mmol/L 10.1 
Samoa 1991 (14) 1,776 Population-based cluster sampling; age: 25–74 years FPG ≥7.8 mmol/L or/and 2-h PG ≥11.1 mmol/L Apia: M:F 9.5:13.4 
Poutasi: M:F 5.3: 5.6 
Tuasivi: M:F 7.0:7.5 
2002 (142,817 WHO STEPS; random sample population-based study; age: 15–64 years Capillary FBG ≥6.1 mmol/L or venous FPG ≥7.0 mmol/L or on medication 22.1 
Singapore 2004 (31) NR National survey; age: 18–69 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 8.2 
2010 (31) NR National survey; age: 18–69 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 11.3 
Solomon Islands 1986 (14243 Population-based study; age ≥18 years WHO STEPS; population-based; age: 25–64 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L 2.09 
2006 (14950 Capillary FBG ≥6.1 mmol/L or on medication 13.5 
Thailand 1991 (32) National Age: ≥30 years FPG ≥7.0 mmol/L 2.3 
2004 (32) National Age: ≥15 years FPG ≥7.0 mmol/L 6.8 
2009 (33) National Age: ≥20 years FPG ≥7.0 mmol/L 7.5 
Tokelau 1976 (14346 Population-based study; age: 35–74 years OGTT (100 g): 1-h PG ≥13.9 mmol/L M:F 7.0:14.3 
2005 (14573 WHO STEPS; population-based national survey; age: 15–64 years Capillary FBG ≥6.1 mmol/L or on medication 33.6 
Tonga 1991 (14) 1,024 National sample; age: ≥15 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L 15.1 
2004 (14) 453 WHO STEPS; population-based national survey; age: 15–64 years Capillary FBG ≥6.1 mmol/L or on medication 16.4 
Vanuatu 1991 (141,378 An occupation-based (civil servants) urban sample and area-based semirural and rural samples; age: NR FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L Vila: M:F 2.1:12.1 
Nguna: M:F 2.1:1.1 
Tanna: M:F 1.0:0.9 
2011 (14) 4,422 WHO STEPS; population-based national survey; survey included all six provinces; age: 25–64 years Capillary FBG ≥6.1 mmol/L or on medication 21.2 
Vietnam 2001 (342,932 Cross-sectional; age ≥15 years FPG ≥7.8 mmol/L or/and 2-h PG ≥11.1 mmol/L 3.8 
FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 
2011 (122,710 Cross-sectional; age: 40–64 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L 3.7 
Wallis and Futuna 1980 (14) 549 Population-based study; age: ≥20 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 2.7 
2010 (14) 487 WHO STEPS; population-based national survey; age: 15–64 years FPG ≥7.0 mmol/L or on medication 17.5 
CountryYear (Ref)Sample size (n)CharacteristicsDiagnostic criteriaDiabetes (%)
American Samoa 2004 (142,072 WHO STEPS; stratified cluster sampling; age: 25–64 years Capillary FPG ≥6.1 mmol/L 47.3 
Australia 2011–2012 (20) NR Age: ≥18 years HbA1c ≥6.5% (≥47.5 mmol/mol) 5.4 
Brunei Darussalam 2003 (21) NR Population-based data from integrated health screening system from medical case records; age: NR Capillary FPG ≥6.1 mmol/L or known diabetes 5.4 
2010 (21) NR Age: ≥20 years Capillary FPG ≥6.1 mmol/L or known diabetes 12.5 
Cambodia 2004 (162,246 Cross-sectional; two communities: rural and semiurban; age: ≥25 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L Rural: 5.0 Suburban: 11.0 
2011 (24) 5,123 WHO STEPS; multistage cluster method (180 clusters); age: 25–65 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L Total: 2.9 (95% CI 2.3–3.4) 
Rural: 2.3 (95% CI 1.7–2.9) 
Urban: 5.6 (95% CI 4.0–7.2) 
China 2001 (25) 15,838 Nationally representative stratified sampling; age: 35–74 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 5.5 
2010 (15) 98,658 Complex, multistage, probability sampling design; age: ≥18 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 11.6 
China, Hong Kong SAR 1990 (221,513 Participants from a public utility company and a regional hospital; age: ≥30 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 4.5 
2007–2010 (233,376 Hong Kong professional driver community project; age: 18–70 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 8.1 
Cook Islands 1980 (141,102 Population-based study; age: ≥20 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 6.8 
2003 (142,036 WHO STEPS; stratified samples; age: NR Capillary FPG ≥6.1 mmol/L or on medication 23.6 
Federated States of Micronesia 1994 (142,188 Population-based study in Kosrae population; age: 20–85 years FPG ≥7.0 mmol/L 12.0 
2002 (141,638 WHO STEPS; population-based cross-sectional study; age: 25–64 years FPG ≥7.0 mmol/L 32.1 
Fiji 2002 (142,277 Population-based multistage sampling in 30 clusters; age: 15–64 years Capillary FPG ≥6.1 mmol/L or on medication; HbA1c ≥6.5% (≥47.5 mmol/mol) or known to have diabetes 16.0 
2009 (141,353 WHO STEPS; population-based study; age: ≥40 years 44.8 
French Polynesia 2010 (143,469 WHO STEPS; population-based multistage sampling; age: 18–64 years Capillary FPG ≥6.1 mmol/L or on medication 7.3 
Indonesia 1997 (18941 Population-based study of government and retired individuals; age: NR FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 5.4 
2009 (1924,417 Samples from 13 urban provinces; age: ≥15 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 5.7 
Japan 1997 (17National Age: ≥20 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L M:F 9.9:7.1 
2007 (17National Age: ≥20 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L M:F 15.3:7.3 
Kiribati 1983 (142,938 Population-based survey; age: ≥20 years; South Tarawa and the four outer islands; age: 15–64 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L Urban: M:F 9.6:8.7 
Rural: M:F 3.0:3.3 
2004–2006 (141,146 WHO STEPS; population- based multistage sampling; age: 18–64 years FPG ≥7.0 mmol/L 28.1 
Malaysia 2006 (2634,539 Malaysian National Health Morbidity Survey (NHMS) III; age: ≥18 years FPG ≥7.1 mmol/L or known to have diabetes 11.6 
2013 (264,341 Two-stage stratified sampling design; age: ≥18 years HbA1c ≥6.5%, FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 22.9 
Marshall Islands 2002 (14994 WHO STEPS; population-based; age: 15–64 years FPG ≥7.0 mmol/L 19.6 
Mongolia 2005 (273,411 WHO STEPS; population-based; age: 15–64 years Capillary FBG ≥6.1 mmol/L or on medication 8.2 
2009 (275,368 WHO STEPS; population-based; age: 15–64 years Capillary FBG ≥6.1 mmol/L or on medication 6.5 
Nauru 1987 (11,201 Population-based data; age: ≥20 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 24.0 
2004 (14883 Systematic random sample design; age: 15–64 years FPG ≥7.0 mmol/L or on medication 16.2 (age 15–24 years) 
22.7 (age 25–64 years) 
New Zealand 2002–2003 (2812,929 Stratified cluster sampling; age: ≥15 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 8.1 
2008–2009 (284,721 Age: ≥15 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 7.0 
Niue 1980 (11,128 Population-based survey; age: ≥20 years FPG ≥7.8 mmol/L 7.2 
2012 (14863 WHO STEPS; population-based; age: ≥15 years Capillary FBG ≥6.1 mmol/L or on medication 38.4 
Papua New Guinea 1991 (14497 Population-based cluster; age: ≥25 years Random blood glucose ≥8 mmol/L or known diabetes Urban: 30.3 
Rural: Wanigela: 11.7 
Kalo: 1.6 
2008 (142,944 WHO STEPS; population-based survey; age: 15–64 years Capillary FBG ≥6.1 mmol/L or on medication 14.4 
Republic of Korea 2005 (294,628 KNHANES; age: ≥30 years FPG ≥7.0 mmol/L or/and history of diabetes 9.1 
2007–2009 (2913,512 Age: ≥30 years FPG ≥7.0 mmol/L 9.9 
2011–2012 (30) 14,330 National Health Survey; age: ≥30 years FPG ≥7.0 mmol/L 10.1 
Samoa 1991 (14) 1,776 Population-based cluster sampling; age: 25–74 years FPG ≥7.8 mmol/L or/and 2-h PG ≥11.1 mmol/L Apia: M:F 9.5:13.4 
Poutasi: M:F 5.3: 5.6 
Tuasivi: M:F 7.0:7.5 
2002 (142,817 WHO STEPS; random sample population-based study; age: 15–64 years Capillary FBG ≥6.1 mmol/L or venous FPG ≥7.0 mmol/L or on medication 22.1 
Singapore 2004 (31) NR National survey; age: 18–69 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 8.2 
2010 (31) NR National survey; age: 18–69 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 11.3 
Solomon Islands 1986 (14243 Population-based study; age ≥18 years WHO STEPS; population-based; age: 25–64 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L 2.09 
2006 (14950 Capillary FBG ≥6.1 mmol/L or on medication 13.5 
Thailand 1991 (32) National Age: ≥30 years FPG ≥7.0 mmol/L 2.3 
2004 (32) National Age: ≥15 years FPG ≥7.0 mmol/L 6.8 
2009 (33) National Age: ≥20 years FPG ≥7.0 mmol/L 7.5 
Tokelau 1976 (14346 Population-based study; age: 35–74 years OGTT (100 g): 1-h PG ≥13.9 mmol/L M:F 7.0:14.3 
2005 (14573 WHO STEPS; population-based national survey; age: 15–64 years Capillary FBG ≥6.1 mmol/L or on medication 33.6 
Tonga 1991 (14) 1,024 National sample; age: ≥15 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L 15.1 
2004 (14) 453 WHO STEPS; population-based national survey; age: 15–64 years Capillary FBG ≥6.1 mmol/L or on medication 16.4 
Vanuatu 1991 (141,378 An occupation-based (civil servants) urban sample and area-based semirural and rural samples; age: NR FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L Vila: M:F 2.1:12.1 
Nguna: M:F 2.1:1.1 
Tanna: M:F 1.0:0.9 
2011 (14) 4,422 WHO STEPS; population-based national survey; survey included all six provinces; age: 25–64 years Capillary FBG ≥6.1 mmol/L or on medication 21.2 
Vietnam 2001 (342,932 Cross-sectional; age ≥15 years FPG ≥7.8 mmol/L or/and 2-h PG ≥11.1 mmol/L 3.8 
FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 
2011 (122,710 Cross-sectional; age: 40–64 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L 3.7 
Wallis and Futuna 1980 (14) 549 Population-based study; age: ≥20 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 2.7 
2010 (14) 487 WHO STEPS; population-based national survey; age: 15–64 years FPG ≥7.0 mmol/L or on medication 17.5 

F, female; FBG, fasting blood glucose; HbA1c, glycated hemoglobin A1c; M, male; NR, not reported; PG, plasma glucose; SAR, Special Administrative Region.

*It needs to be recognized that only broad comparisons can be made from these data owing to significant differences in age-groups, survey methodologies, diagnostic criteria, etc.

†National studies.

In the 2013 IDF estimates, China tops the global list of countries for the total number of people with diabetes, followed by India (2). The number of people with diabetes in Japan has increased significantly since 1997, especially among the male population. In 2013, it occupied the 10th position in the IDF list, with 7.2 million people with diabetes (17). Indonesia has not registered a significant increase since 1997 (18,19).

IDF estimates for diabetes within the Pacific vary widely, from the world’s highest of 47.3% in American Samoa to a comparatively lower prevalence of 7.3% in French Polynesia (3,10). Figure 1 shows the map of the WPR, and Table 2 reports the temporal changes in the prevalence of diabetes in these countries. The rising trend in the developing countries is considerably steeper compared with the developed countries (1,12,14,15,1734). In recent decades, apart from the WHO STEPS studies (11), there have been very few national diabetes studies for the Pacific Ocean nations (14). Nevertheless, some of the highest estimates of prevalence globally continue to be seen in this region, even though the use of FPG alone underestimates the true diabetes prevalence (35) and the laboratory methods were not standardized among the studies.

Obesity is a major driver of the T2DM epidemic, and the Pacific Island nations are among the leaders in the world obesity and diabetes charts (14). According to the latest WHO criteria for obesity (11), more than 70% of the people in American Samoa, Nauru, and Tokelau are obese. Other islands also show a high prevalence of obesity, including Kiribati (50.6%), the Marshall Islands (45%), the Federated States of Micronesia (42.6%), the Solomon Islands (32.8%), and Fiji (29.6%) (14).

Since the 1960s, the Pacific region has been recognized as a “hot spot” for diabetes, with Prior and Davidson (36) first reporting a higher diabetes prevalence in Polynesians compared with New Zealanders of European descent. In 1975, on the Central Pacific island of Nauru, the then highest ever national diabetes prevalence of 34.4% was reported (37). Income from Nauru’s rich phosphate deposits had resulted in its Micronesian population becoming extremely prosperous and obese. With the phosphate deposits now exhausted, and with the consequent contraction of the national economy, a significant fall has occurred in diabetes prevalence (1). In the 1980s, Zimmet et al. (38) confirmed the higher prevalence of diabetes in other Pacific Islands using standardized protocols. However, because most of these studies were undertaken more than two decades ago, they are unlikely to reflect current diabetes rates (14).

The paucity of secular data in the Pacific presents a difficulty in monitoring trends. The age-standardized prevalence of T2DM in Western Samoa increased between 1978 and 1991 from 8.1 to 9.5% in men and from 8.2% to 13.4% in women in the urban area, and from 2.3% to 7% in men and from 4.4% to 7.5% in women in a rural community (39). In Tonga in 2002, Colagiuri et al. (40) reported a dramatic secular increase (100% in 25 years) in diabetes from 7.5% in 1973% to 15.1%, of which 80% were undiagnosed cases.

King et al. (16), in 2005, reported on diabetes in Cambodia, a relatively poor and fairly traditional country, showing prevalence of 5% (rural) and 11% (semiurban). The prevalence of IGT was 10% (rural) and 15% (semiurban). About two-thirds of all cases of diabetes were undiagnosed. These figures are much higher than those reported by a subsequent WHO STEPS study (11). Such differences, which may relate to the first study being a dedicated diabetes survey and using the OGTT and the second study being a general survey of noncommunicable diseases and relying on the fasting glucose alone, need to be kept in mind.

In Malaysia, the reported prevalence of diabetes was 11.6% in 2006 (26), 15.2% (8% undiagnosed) in the 2011 national study (41), and 22.9% in 2013 (26). The age distribution of the study groups was similar. The higher prevalence seen in the 2013 survey may partly be explained by the use of the OGTT. In Thailand, the National Health Examination Survey showed that the diabetes prevalence in people aged ≥15 increased from 2.5% in 1991 to 4.6% in 1997 and to 6.8% in 2004 (32). In 2009, their National Health Examination Survey (33) found the prevalence of impaired fasting glucose was 10.6% and diabetes was 7.5% (of which 35.4% were undiagnosed cases) in adults aged ≥20 years. These prevalences were likely to be underestimates because diagnosis relied only on a single FPG, history of physician diagnosis, and information on medications (33). The age-standardized prevalence in Singapore has remained constant at ∼11% during the last two decades. In Singapore, diabetes was more common in Indians (17.2%) than in Malays (16.6%) or Chinese (9.7%) (31).

The prevalence of diabetes in Korea increased from <1% in 1960 to >10% by early 2000. The Korea National Health and Nutrition Examination Survey (KNHANES) 2010–2012 also reported a prevalence of 10.1% based on FPG (29,30), suggesting a constant prevalence of diabetes during the last decade. Diabetes was more prevalent in individuals in lower socioeconomic groups, a finding similar to that in developed Western countries.

South Asia

South Asia constitutes one-fifth of the world’s population and includes nine countries, all of which are undergoing lifestyle transitions that make their populations more vulnerable to develop T2DM. In the last few decades, the diabetes prevalence in South Asia has also risen considerably. Table 3 reports the secular changes that occurred in these nations (5,4251). However, true nationally representative data, which include urban and rural prevalence, are lacking from most of these countries, including India.

Table 3

Prevalence of diabetes in South Asia, with temporal changes shown wherever available

CountryYear (Ref)Sample size (n)CharacteristicsDiagnostic criteriaDiabetes (%)
Afghanistan 2013 (421,169 Age: >40 years Capillary FBG ≥6.1 mmol/L or on medication 13.3 
Bangladesh 2005 (56,312 Cross-sectional; age: ≥20 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L Urban: 8.3 
Rural: 2.3 
2011 (43)* 8,835 Population-based national survey; age: ≥35 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 9.7 
Bhutan 2008 (442,474 Stratified two-stage sampling; age: 25–74 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L 8.2 
India 2000 (4511,216 Random sampling, six metropolitan cities; age: ≥20 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L 12.1 
2008–10 (4613,055 Stratified multistage sampling (188 urban, 175 rural) in three states and one union territory; age not reported Fasting CBG ≥7 mmol/L or/and 2-h CBG ≥12.2 mmol/L or on medication Tamil Nadu: 10.4 
Maharashtra: 8.4 
Jharkhand: 5.3 
Chandigarh: 13.6 
Maldives 2004 (47)* 1,556 Cross-sectional; national; age: 25–64 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L 4.5 
Mauritius 1987 (485,083 Independent population-based survey; age: 20–74 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 13.0 
2009 (486,371 Age: 20–74 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 21.3 
Nepal 2011 (4914,425 Population from Eastern Nepal; age: >20–100 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 6.3 
Pakistan 2000 (501,042 Age: 30–64 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 6.5 
2006 (505,433 Age: 30–64 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L Urban: 10.6 
Rural: 7.7 
Sri Lanka 2001 (56,047 Cross-sectional; stratified random samples from four provinces; age: ≥30 years FPG ≥7.0 mmol/L or on medication 13.8 
 
2006 (51)* 4,532 Cross-sectional; national representative; age: ≥20 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 10.3 
CountryYear (Ref)Sample size (n)CharacteristicsDiagnostic criteriaDiabetes (%)
Afghanistan 2013 (421,169 Age: >40 years Capillary FBG ≥6.1 mmol/L or on medication 13.3 
Bangladesh 2005 (56,312 Cross-sectional; age: ≥20 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L Urban: 8.3 
Rural: 2.3 
2011 (43)* 8,835 Population-based national survey; age: ≥35 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 9.7 
Bhutan 2008 (442,474 Stratified two-stage sampling; age: 25–74 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L 8.2 
India 2000 (4511,216 Random sampling, six metropolitan cities; age: ≥20 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L 12.1 
2008–10 (4613,055 Stratified multistage sampling (188 urban, 175 rural) in three states and one union territory; age not reported Fasting CBG ≥7 mmol/L or/and 2-h CBG ≥12.2 mmol/L or on medication Tamil Nadu: 10.4 
Maharashtra: 8.4 
Jharkhand: 5.3 
Chandigarh: 13.6 
Maldives 2004 (47)* 1,556 Cross-sectional; national; age: 25–64 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L 4.5 
Mauritius 1987 (485,083 Independent population-based survey; age: 20–74 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 13.0 
2009 (486,371 Age: 20–74 years FPG ≥7.8 mmol/L or 2-h PG ≥11.1 mmol/L 21.3 
Nepal 2011 (4914,425 Population from Eastern Nepal; age: >20–100 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 6.3 
Pakistan 2000 (501,042 Age: 30–64 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 6.5 
2006 (505,433 Age: 30–64 years FPG ≥7.0 mmol/L or/and 2-h PG ≥11.1 mmol/L Urban: 10.6 
Rural: 7.7 
Sri Lanka 2001 (56,047 Cross-sectional; stratified random samples from four provinces; age: ≥30 years FPG ≥7.0 mmol/L or on medication 13.8 
 
2006 (51)* 4,532 Cross-sectional; national representative; age: ≥20 years FPG ≥7.0 mmol/L or 2-h PG ≥11.1 mmol/L 10.3 

CBG, capillary blood glucose; FBG, fasting blood glucose; PG, plasma glucose.

*National study.

South Asian populations also have a high prevalence of prediabetes and a more rapid progression to diabetes (13). This is highlighted by a recent study that reported a diabetes incidence of 22.2 per 1,000 person-years and that 59% of those with prediabetes converted to diabetes after a follow-up of 9.1 years (52).

A 2008 report from Southern India showed a marked increase in diabetes prevalence in both urban and rural areas compared with earlier studies (53). Studies from other parts of India have also shown increases in diabetes prevalence (13,46).

India is the largest country in the region and has more than 65.1 million people with diabetes, occupying the second position next to China in the IDF global list of top 10 countries for people with diabetes. Pakistan and Bangladesh are in 12th and 13th positions, respectively (10). The IDF estimates that the number of people with diabetes in South Asia will increase to 120.9 million, 10.2% of the adult population, by 2030. The highest increase in diabetes prevalence is noted in Mauritius (48) (Table 3), an Indian Ocean island with a predominantly Asian Indian population. A survey conducted in urban and rural Maldives showed that the prevalence of diabetes was 10.6% (47). However results from the STEPS survey conducted in Male, the Maldives capital city, showed the prevalence of diabetes was 4.5% in all adults (11). Again, the reason for the difference seen in the STEPS study is unclear.

Several distinctive features are noted among the South Asians, such as early occurrence of diabetes at lower BMI levels (6), higher rates of insulin resistance, abdominal obesity, and familial aggregation of diabetes than in many other ethnic groups. In recent decades, an increasing diabetes prevalence has been reported in rural areas in middle-income groups and among underprivileged people (13,51). Occurrence of T2DM at a young age is commonly observed among South Asians, with the picture further complicated by the presence of maturity-onset diabetes of the young or latent autoimmune diabetes of adulthood (13).

Urban-Rural Difference

In developing countries in Asia and WPR, the urban-rural difference in diabetes prevalence is narrowing due to the increasing reach of Western lifestyles and associated behavioral changes into rural settings. In India, Nepal, Sri Lanka, the Solomon Islands, Samoa, and Thailand, more than 50% of the national population with diabetes resides in rural areas (10). Recent studies from India (53) and China (4,6,54) have shown greater rates of increase in diabetes prevalence in rural than in urban areas. Hwang et al. (55) reported that across multiple surveys, there was evidence of a fivefold rise in the prevalence of diabetes from 1985 to 2010 in rural populations of developing countries.

Diabetes in the Diaspora

Population-based studies indicate a higher prevalence of diabetes among the South Asian diaspora compared with other ethnic and the local populations in many Western nations, including the U.S. and the U.K. (13,5660). Among South Asians, T2DM is usually diagnosed at an earlier age and is associated with increased mortality compared with the white population in these countries.

Risk Factors for Diabetes in Asians and Pacific Islanders

Similar risk factors for T2DM have been identified in Europids and in Asian populations (5,6,54). Many of these risk factors are closely linked to economic development and the increasing urbanization seen across much of Asia and the Pacific. Some risk factors for T2DM have become of great concern among developing countries in Asia and the Pacific. As discussed later, the prevalence of GDM has also increased markedly in Asia and the Pacific in recent decades (9,10).

Much of the recent increase in diabetes prevalence is related to changes in dietary pattern, sedentary behavior, and obesity superimposed on a background of genetic/epigenetic susceptibility (61). Most Asian countries have witnessed, to different degrees, a nutritional transition, with increases in intake of refined carbohydrates, animal fats, and meat, and reduced consumption of dietary fiber and vegetables (61,62). Similar to the U.S., the consumption of sugar-sweetened beverages in China has increased dramatically during the last few decades (62).

Several dietary risk factors may be particularly relevant to Asians. The South Asian diet, characterized by high intake of carbohydrates, trans fats, and saturated fats (63), appears particularly conducive to the risk of T2DM. White rice constitutes up to 60% of the glycemic load among the Chinese and was found to be associated with an increased risk of diabetes in a meta-analysis (64). This association between white rice intake and risk of T2DM was also noted in India (65). Although rice has been a staple food for centuries, there has been a shift to increased intake of polished rice, which produces a greater glycemic excursion than do the more traditional types of rice. Furthermore, Asians appear to have greater glycemic excursion to white rice compared with other populations (66).

Physical inactivity is an important risk factor for T2DM in most populations (4,5). With increasing urbanization, physical activity has declined, particularly in occupational settings (67), and sedentary behavior has increased. This highlights the importance of encouraging physical activity and reducing sedentary behavior in large-scale community diabetes prevention initiatives in Asia and the Pacific.

Studies that have examined the association between adiposity and diabetes in multiethnic cohorts noted that Asians develop diabetes at a considerably lower BMI compared with Europids (54,68). This is ascribed to visceral adiposity in Asian populations (69). As a result, in Asians, lower BMI cutoffs are being used to define obesity (70) as well as lower waist circumference for defining central obesity (57,70). However, two large observational studies have shown that the incremental risk of diabetes associated with increasing adiposity does not differ between Europid and Asian populations (71,72). Thus, the ethnic difference in the adiposity-diabetes relationship is probably better characterized as an increased risk of diabetes at all levels of BMI (or waist circumference) rather than as diabetes occurring at lower levels of BMI. It is very similar to the increased diabetes risk of Asian populations seen at all ages, and both observations point to factors other than those related to obesity or age that increase diabetes susceptibility in Asian populations.

Several novel putative risk factors have recently emerged as important behavioral and environmental determinants for T2DM. These include sleep disturbances and environmental exposure to organic pollutants and other chemicals (62). Given the major problems of pollution in many developing countries, the latter has the potential to be an important contributor to the diabetes epidemic during adult life or as an in utero exposure.

Developmental Origins of T2DM: Relevance in Asia and Pacific Communities

The initial observations on the association between low birth weight and adult risk of diabetes and metabolic disturbances were made by Hales and Barker (73). It is now increasingly appreciated that the in utero environment plays an important role in modifying developmental trajectory and physiology, thereby altering the risk of obesity, T2DM, and other chronic diseases in adulthood (7).

Studies in relation to the Dutch winter (74) and Chinese (75) famines provide support for the hypothesis that nutritional deprivation in utero may predispose an individual to T2DM in adult life. In those exposed to severe famine in some parts of China during early life, there is a marked increase in the risk of diabetes as adults compared with those not exposed to the same severe nutritional restriction during in utero development. This risk of diabetes in midlife is highest among offspring exposed to in utero undernutrition and who were subsequently exposed to an affluent diet (75). This phenomenon of historical exposure to undernutrition in early life followed by exposure to a “metabolically challenging” environment characterized by an energy-dense diet may be highly relevant to the current high rates of T2DM in parts of Asia and the Pacific.

The emergence of T2DM in Cambodia at rates similar to those in developed nations (16) came decades after the political and socioeconomic upheaval caused severe food shortages in Cambodia in 1975. During World War II, the Nauruans were subjected to famine conditions on Nauru and on other Pacific Islands, such as Truk, where they had been relocated. Some three decades later, Nauru had the highest diabetes prevalence in the world (37). These historical examples show the potential of unexpected health outcomes from wars and famine when later followed by relative overnutrition. Furthermore, the study by Yajnik (76) in India strongly suggest that early development issues and epigenetics may play an important role in the contemporary burden of diabetes experienced in India.

In addition to a link between in utero undernutrition and offspring risk, epidemiological studies, particularly among the Pima Indians, have highlighted increased risk of obesity and T2DM in offspring exposed to maternal diabetes or obesity (7779). This is also particularly relevant in Asia, where there is a higher proportion of young-onset diabetes and a higher prevalence of GDM compared with Europe and the U.S. (9). Thus, intergenerational cycles may operate in Asia to increase the risk of diabetes in future generations (76).

GDM

With the epidemiological transitions occurring in Asia, leading to a younger age of diabetes onset, the burden of pregnancy complicated by hyperglycemia is increasing (80). Hyperglycemia in pregnancy includes cases of diabetes predating pregnancy as well as GDM. On the basis of a systematic literature review of studies reporting the prevalence of GDM in different countries, the IDF estimated that 16% of pregnancies globally were affected by hyperglycemia in 2013, with a crude prevalence of 11.8% in the IDF WPR and 23.1% in the South Asian region (80). The prevalence of GDM reported in Asia has ranged from 1% to more than 20%, depending on the period, ethnicity, and population in which the study was conducted, as well as the screening strategy and diagnostic criteria being used, which has been extensively reviewed elsewhere (9). A study from Australia comparing women of different ethnicities with a diagnosis of GDM noted that women from Southeast Asia had the lowest BMI and were more likely to be diagnosed based on elevated 2-h glucose during OGTT, whereas women from Pacific Islands and Anglo-Europeans had the highest BMI and were more likely to be diagnosed based on elevated fasting glucose (81).

A marked secular increase in prevalence of GDM has been reported in several studies; for example, universal screening of pregnant women for GDM in Tianjin, China, showed that the prevalence increased markedly from 2.4 to 6.8% from 1999 to 2008 (82). Use of the diagnostic criteria proposed by the International Association of the Diabetes and Pregnancy Study Groups (IADPSG), recently adopted by the WHO (83), is likely to lead to further increases in GDM prevalence. In a study from Vietnam, for example, applying the IADPSG criteria resulted in an increase in prevalence of GDM from 6.1 to 20.3% (84).

The offspring of mothers with GDM have increased risks of obesity, hypertension, diabetes, and other noncommunicable diseases (78,79). Given the high risk of GDM among Asian populations and the potential transgenerational effects of GDM and maternal nutrition, there is an urgent need to implement preconception interventions to optimize maternal health (85,86). Also, the high prevalence of GDM and its potential long-term effects makes a strong case for universal screening for GDM in Asian populations. This has already been adopted in some Asian countries (9).

Pattern of Diabetes Complications in Asia and Pacific Communities

There are ethnic differences in the pattern of diabetes complications (54). Early observations from the WHO Multinational Study of Vascular Disease in Diabetes (WHO MSVDD) had suggested comparatively high rates of albuminuria in Asian centers (87). In an analysis of 65,171 subjects with T2DM evaluated in primary care in New Zealand between 2000 and 2006 (including 3,166 South Asians and 1,941 East Asians), the risks of having microalbuminuria, macroalbuminuria, and advanced proteinuria were significantly increased 1.4- to 4-fold in Pacific Islanders, South Asians, and East Asians compared with Europeans (88). Moreover, recent studies in multiethnic populations that compared diabetic renal disease among individuals of different ethnicities suggest that ethnic minorities in the U.S., including South Asians and Chinese, are more likely to suffer from proteinuric diabetic renal disease than from nonproteinuric diabetic renal disease (89).

A meta-analysis of studies on the prevalence of diabetic retinopathy noted that South Asians had the lowest prevalence (90). A lower prevalence of peripheral sensory neuropathy was also reported in Asian patients in the Fremantle Diabetes Study (FDS) in Australia compared with patients of European descent (91).

The prevalence of diabetes complications in the Pacific region is higher than that reported for other regions (e.g., Asia, Africa, and the Middle East) (14). Consistent with this, Pacific Islanders in the U.S. have a comparatively high prevalence of foot complications and amputations (92).

In the WHO MSVDD, the prevalence of cardiovascular complications was high in South Asians, but in general was low in centers in China, Hong Kong, and Japan (93). More recent studies have confirmed these earlier observations. For example, other studies in multiethnic populations have noted the high prevalence of cardiovascular complications among South Asian populations, believed to be partly driven by their predisposition to visceral adiposity (6,13). In contrast, patients with T2DM in China appear to have lower rates of cardiovascular complications compared with Europeans (94), and the application to Chinese populations of risk scores developed in European populations tends to overestimate the risk of coronary heart disease (95). Studies that have compared the risk of peripheral vascular disease have noted that South Asians are at lower risk of amputations than Europeans (96).

In addition to ethnic differences in the risk of diabetes complications, the pattern of diabetes complications in Asia is also notable for the large proportion of individuals with young-onset T2DM. In the Joint Asia Diabetes Evaluation (JADE) program, among 41,029 patients recruited from across nine countries/regions in Asia, 18% had onset of T2DM below the age of 40 (97), had longer disease duration, and had higher rates of retinopathy and end-stage renal disease than those with onset of diabetes after the age of 40 (97). In the Hong Kong Diabetes Registry, patients with young-onset diabetes had higher risks of incident cardiovascular and renal complications at any age, driven by the longer disease duration (98). Given the proportion of patients with young-onset T2DM, the potential burden of diabetes-related complications is of great concern.

Prevention of Diabetes

Primary prevention of diabetes is a practical and cost-effective method of reducing incident diabetes in populations of varied ethnicity and biological characteristics (99). Systematic long-term studies conducted in Western nations, such as the U.S. (100) and Finland (101), have shown the benefits of using intensive lifestyle modification (LSM) resulting in significant weight reduction in obese and overweight persons with IGT, leading to a 58% relative risk reduction in diabetes (100). These programs in the Western countries (100) and in China have also shown the enduring effect of LSM, with the effects demonstrated to last at least 10–20 years (102,103).

Studies in the Asian populations, such as the Da Qing studies in China (102,103), the Indian Diabetes Prevention Programme (IDPP) (104) in India, and the Japanese prevention programs (105,106), have shown that LSM is effective in preventing T2DM even in nonobese populations with high levels of insulin resistance and that this is achieved without significant weight reduction. Importantly, the 23-year Da Qing IGT and Diabetes Study follow-up showed a sustained beneficial effect of LSM on diabetes incidence and on cardiovascular and all-cause mortality in the Chinese population (102). Pragmatic, cost-effective, and scalable programs are being tested in developed countries and in South Asian countries (107). A recent study in India showed that the cumulative incidence of diabetes in 2 years was significantly lower among the people with prediabetes who received frequent text messages on mobile phones on healthy lifestyle principles (18%) than among the control group on standard care (27%) (108). Table 4 describes the major diabetes prevention studies in Asia using LSM (102106,108).

Table 4

Randomized controlled prevention studies in T2DM in Asian populations using lifestyle intervention

Study population characteristicsMean durationParticipants by treatment groupCumulative incidence of diabetesRelative risk reduction
Study (year) (Ref)(years)(n)(%)(%)
Da Qing IGT and Diabetes Study (1997) (102Chinese:  Total n = 577 Control: 67.7 Diet: 31.0 
BMI: 26.0 Control: 133 Diet: 43.8 Exercise: 46.0 
Age: 45.0  Diet: 130 Exercise: 41.1 Diet + exercise: 42.0 
Cluster randomized by clinic  Exercise: 141 Diet + exercise: 46.0  
  Diet + exercise: 126   
Da Qing Diabetes Prevention Study (2008) (103Control  Control: 138 Control: 93.0 43.0 
BMI: 24.4 20 Intervention: 439 Intervention: 80.0  
Intervention     
BMI: 24.5     
Da Qing Diabetes Prevention Study (2014) (103Control  Total n = 568 (by interview from medical records) Control: 89.9 45.0 
BMI: 25.7 23 Control: 138 Intervention: 72.6  
Intervention  Intervention: 430 CVD mortality 41.0 
BMI: 26.2   Control: 19.6  
 Intervention: 11.9  
   All-cause mortality 29.0 
   Control: 38.4  
   Intervention: 28.0  
IDPP-1 (2006) (104BMI: 25.8 2.6 (median) Total n = 531 Control: 55.0 LSM: 28.5 
Age: 45.9  Control: 136 LSM: 39.3 Metformin: 26.4 
Persistent IGT, individual randomization  LSM: 133 Metformin: 40.5 LSM + metformin: 28.2 
  Metformin: 133 LSM + metformin: 39.5  
  LSM + metformin: 129   
Indian SMS study (2013) (108BMI: 25.8 Control: 266 Control: 27.4  
Age: 45.9  Intervention: 271 Intervention: 18.5 36.0 
Persistent IGT, men     
Japanese prevention study (2005) (105Japanese men: Control: 102 Control: 9.3 67.4 
BMI: 23.5 Intervention: 356 Intervention: 3.0 
Age: 51.5 
IGT, individual randomization 
Zensharen Study for Prevention of Lifestyle Diseases (2011) (106Japanese men: Control: 330 Control: 16.6 44.0 
BMI: 27.0 Intervention: 311 Intervention: 12.2 
 Age: 49.0 
IGT, individual randomization 
Study population characteristicsMean durationParticipants by treatment groupCumulative incidence of diabetesRelative risk reduction
Study (year) (Ref)(years)(n)(%)(%)
Da Qing IGT and Diabetes Study (1997) (102Chinese:  Total n = 577 Control: 67.7 Diet: 31.0 
BMI: 26.0 Control: 133 Diet: 43.8 Exercise: 46.0 
Age: 45.0  Diet: 130 Exercise: 41.1 Diet + exercise: 42.0 
Cluster randomized by clinic  Exercise: 141 Diet + exercise: 46.0  
  Diet + exercise: 126   
Da Qing Diabetes Prevention Study (2008) (103Control  Control: 138 Control: 93.0 43.0 
BMI: 24.4 20 Intervention: 439 Intervention: 80.0  
Intervention     
BMI: 24.5     
Da Qing Diabetes Prevention Study (2014) (103Control  Total n = 568 (by interview from medical records) Control: 89.9 45.0 
BMI: 25.7 23 Control: 138 Intervention: 72.6  
Intervention  Intervention: 430 CVD mortality 41.0 
BMI: 26.2   Control: 19.6  
 Intervention: 11.9  
   All-cause mortality 29.0 
   Control: 38.4  
   Intervention: 28.0  
IDPP-1 (2006) (104BMI: 25.8 2.6 (median) Total n = 531 Control: 55.0 LSM: 28.5 
Age: 45.9  Control: 136 LSM: 39.3 Metformin: 26.4 
Persistent IGT, individual randomization  LSM: 133 Metformin: 40.5 LSM + metformin: 28.2 
  Metformin: 133 LSM + metformin: 39.5  
  LSM + metformin: 129   
Indian SMS study (2013) (108BMI: 25.8 Control: 266 Control: 27.4  
Age: 45.9  Intervention: 271 Intervention: 18.5 36.0 
Persistent IGT, men     
Japanese prevention study (2005) (105Japanese men: Control: 102 Control: 9.3 67.4 
BMI: 23.5 Intervention: 356 Intervention: 3.0 
Age: 51.5 
IGT, individual randomization 
Zensharen Study for Prevention of Lifestyle Diseases (2011) (106Japanese men: Control: 330 Control: 16.6 44.0 
BMI: 27.0 Intervention: 311 Intervention: 12.2 
 Age: 49.0 
IGT, individual randomization 

Age given as mean (years) and BMI given as mean (kg/m2). CVD, cardiovascular disease.

For any program to be successful at a population level, major changes are required at relevant personal, cultural, societal, and community levels (109). An example of the principles laid out in the Western Pacific Declaration on Diabetes (110) being translated in action can be found in Singapore’s diabetes prevention efforts discussed below.

Preventing Diabetes in Singapore

According to the 2010 Singapore National Health Survey, the crude diabetes prevalence increased from 8.6% in 1992 to 11.3% in 2010 (111). However, the age-standardized prevalence remained constant at ∼11% during the two decades. Obesity prevalence has been rising in the last decade from 6 to 11%. The effect of rising obesity on diabetes prevalence will likely only be evident in one to two decades. It is estimated that Singapore will have half a million people with diabetes by 2020 and that this will rise to 1 million by 2050, double an earlier projection that was based on aging alone (112). The public health policy implication is clearly not just toward increasing the capability of dealing with diabetes once it has arisen (increased capacity and new models of care) but also moving upstream to primary prevention.

The traditional approach to preventing lifestyle-related diseases in Singapore is to provide public education with a strong emphasis on individual responsibility. Singapore’s Healthier Hawker Program provides a case study of this approach. It is part of The Healthy Living Master Plan, a major paradigm shift recognizing the need for multisectoral and integrated approaches to intervention.

Hawker centers are a quintessential feature of the Singaporean food landscape and house a variety of cooked food stalls popular for their convenience, competitive prices, and diversity. In 2010, ∼60% of Singaporeans ate at least four times per week at hawker centers, food courts, and coffee shop stalls. Improving the nutritional quality of foods sold at hawker centers provides an important opportunity for widespread dietary modification among Singaporeans (113).

The traditional model of workplace safety and health in Singapore is focused on prevention of accidents and occupational diseases. However, with the increasing incidence and earlier onset of diabetes and delay in the retirement age, there will be an increasing number of people with diabetes in the working population. It was estimated that there were 180,000 people with diabetes in Singapore’s working population in 2010. The cost to the economy was $1 billion, primarily due to productivity loss. This is of major concern not only to the government but also individual employers. The Total Workplace Safety and Health (TWSH) system was launched jointly by the Ministries of Manpower and Health as a national program to provide a new model of care for the safety and health of the working population (114).

The scenario presented in this review poses huge social and economic problems to most nations in Asia and the Pacific and is likely to impede national and indeed regional and global development. More action, particularly research, is required to understand the drivers of the epidemic, particularly those relating to developmental origins of T2DM, to provide a rationale for prevention strategies to address this rising public health “tsunami.” Primordial prevention strategies instituted in potential mothers, through prevention of malnutrition in utero and in childhood, and through healthy diets and adequate physical activity (“life course approach”) are important additional elements to be included in future strategies for T2DM prevention (85). More action is also needed to effectively implement lifestyle changes on a societal level to stem the tide of the epidemic. Unless drastic steps are taken through national prevention programs in Asia and the Pacific to curb the escalating trends in all of the countries, the social, economic, and health care challenges will be insurmountable (1).

Because estimates of the diabetes burden have important implications for future public health planning, it is essential that such estimates provide reliable data. This review highlights the paucity of these data in a number of Asian and Pacific nations and the need for improving the collection of epidemiological data and its interpretation for public health planning to resource and direct urgently needed prevention activities. This applies particularly to lower- and middle-income nations in these regions. India and China already have a huge burden from diabetes, and they provide the largest diaspora communities worldwide. What is already happening in Asia and the Pacific in terms of the diabetes epidemic and the complications and socioeconomic outcomes provides a daunting lesson for what can happen globally.

Funding. R.C.W.M. acknowledges support from the Research Grants Council Theme-based Research Scheme (T12-402/13N), the Research Grants Council General Research Fund (CU471713), and the European Foundation for the Study of Diabetes/Chinese Diabetes Society/Lilly Programme for Collaborative Research Between China and Europe. J.E.S. is supported by a National Health and Medical Research Council Senior Research Fellowship.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. A.N., R.C.W.M., K.S.C., J.E.S., and P.Z.Z. researched data, contributed to discussion, and wrote, reviewed, and edited the manuscript. A.R., C.S., and J.C.N.C. contributed to discussion and reviewed and edited the manuscript. All authors approved submission of the manuscript for publication.

1.
Zimmet
PZ
,
Magliano
DJ
,
Herman
WH
,
Shaw
JE
.
Diabetes: a 21st century challenge
.
Lancet Diabetes Endocrinol
2014
;
2
:
56
64
[PubMed]
2.
Guariguata
L
,
Whiting
DR
,
Hambleton
I
,
Beagley
J
,
Linnenkamp
U
,
Shaw
JE
.
Global estimates of diabetes prevalence for 2013 and projections for 2035
.
Diabetes Res Clin Pract
2014
;
103
:
137
149
[PubMed]
3.
Chan
JC
,
Cho
NH
,
Tajima
N
,
Shaw
J
.
Diabetes in the Western Pacific Region--past, present and future
.
Diabetes Res Clin Pract
2014
;
103
:
244
255
[PubMed]
4.
Chan
JC
,
Malik
V
,
Jia
W
, et al
.
Diabetes in Asia: epidemiology, risk factors, and pathophysiology
.
JAMA
2009
;
301
:
2129
2140
[PubMed]
5.
Ramachandran
A
,
Snehalatha
C
,
Ma
RC
.
Diabetes in South-East Asia: an update
.
Diabetes Res Clin Pract
2014
;
103
:
231
237
[PubMed]
6.
Ramachandran
A
,
Ma
RCW
,
Snehalatha
C
.
Diabetes in Asia
.
Lancet
2010
;
375
:
408
418
[PubMed]
7.
Gluckman
PD
,
Hanson
MA
,
Cooper
C
,
Thornburg
KL
.
Effect of in utero and early-life conditions on adult health and disease
.
N Engl J Med
2008
;
359
:
61
73
[PubMed]
8.
Chan
JCN
,
Yeung
R
,
Luk
A
.
The Asian diabetes phenotypes: challenges and opportunities
.
Diabetes Res Clin Pract
2014
;
105
:
135
139
[PubMed]
9.
Tutino
GE
,
Tam
WH
,
Yang
X
,
Chan
JC
,
Lao
TT
,
Ma
RC
.
Diabetes and pregnancy: perspectives from Asia
.
Diabet Med
2014
;
31
:
302
318
[PubMed]
10.
International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels, Belgium, International Diabetes Federation, 2013. Available from www.idf.org/diabetesatlas. Accessed 31 March 2014
11.
World Health Organization. STEPS country reports [Internet]. Available from http://www.who.int/chp/steps/reports/en/. Accessed 31 March 2014
12.
Sherwin
RS
,
Anderson
RM
,
Buse
JB
, et al.;
American Diabetes Association
.
The prevention or delay of type 2 diabetes
.
Diabetes Care
2003
;
26
(
Suppl. 1
):
S62
S69
[PubMed]
13.
Misra
A
,
Ramchandran
A
,
Jayawardena
R
,
Shrivastava
U
,
Snehalatha
C
.
Diabetes in South Asians
.
Diabet Med
2014
;
31
:
1153
1162
[PubMed]
14.
Tin
ST
,
Lee
CM
,
Colagiuri
R
.
A profile of diabetes in Pacific Island Countries and Territories
.
Diabetes Res Clin Pract
2015
;
107
:
233
246
[PubMed]
15.
Xu
Y
,
Wang
L
,
He
J
, et al.;
2010 China Noncommunicable Disease Surveillance Group
.
Prevalence and control of diabetes in Chinese adults
.
JAMA
2013
;
310
:
948
959
[PubMed]
16.
King
H
,
Keuky
L
,
Seng
S
,
Khun
T
,
Roglic
G
,
Pinget
M
.
Diabetes and associated disorders in Cambodia: two epidemiological surveys
.
Lancet
2005
;
366
:
1633
1639
[PubMed]
17.
Morimoto
A
,
Nishimura
R
,
Tajima
N
.
Trends in the epidemiology of patients with diabetes in Japan
.
Japan Med Assoc J
2010
;
53
:
36
40
18.
Adam
FM
,
Adam
JM
,
Pandeleki
N
,
Mappangara
I
.
Asymptomatic diabetes: the difference between population-based and office-based screening
.
Acta Med Indones
2006
;
38
:
67
71
[PubMed]
19.
Mihardja
L
,
Delima
,
Manz
HS
,
Ghani
L
,
Soegondo
S
.
Prevalence and determinants of diabetes mellitus and impaired glucose tolerance in Indonesia (a part of basic health research/Riskesdas)
.
Acta Med Indones
2009
;
41
:
169
174
[PubMed]
20.
Australian Bureau of Statistics. Australian Health Survey: Biomedical results for chronic diseases, 2011-12 [article online]. Available from http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/4364.0.55.0052011-12. Accessed 31 March 2015
21.
Ministry of Health Brunei Darussalam. Health Information Booklet 2010. Bandar Seri Begawan, Brunei Darussalam, 2010. Available from http://www.moh.gov.bn/SiteCollectionDocuments/Health%20Indicator%20Booklet/HIB_2010.pdf. Accessed 12 April 2015
22.
Ramachandran
A
,
Snehalatha
C
,
Shetty
AS
,
Nanditha
A
.
Trends in prevalence of diabetes in Asian countries
.
World J Diabetes
2012
;
3
:
110
117
[PubMed]
23.
Siu
SC
,
Wong
KW
,
Lee
KF
, et al
.
Prevalence of undiagnosed diabetes mellitus and cardiovascular risk factors in Hong Kong professional drivers
.
Diabetes Res Clin Pract
2012
;
96
:
60
67
[PubMed]
24.
University of Health Sciences and the Preventive Medicine Department of the Ministry of Health, Kingdom of Cambodia. Prevalence of Non-Communicable Disease Risk Factors in Cambodia. World Health Organization STEPS Survey, Country Report. World Health Organization, Geneva, Switzerland, September 2010. Available from http://www.who.int/chp/steps/2010_STEPS_Report_Cambodia.pdf. Accessed 12 April 2015
25.
Hu
D
,
Sun
L
,
Fu
P
, et al
.
Prevalence and risk factors for type 2 diabetes mellitus in the Chinese adult population: the InterASIA Study
.
Diabetes Res Clin Pract
2009
;
84
:
288
295
[PubMed]
26.
Wan Nazaimoon
WM
,
Md Isa
SH
,
Wan Mohamad
WB
, et al
.
Prevalence of diabetes in Malaysia and usefulness of HbA1c as a diagnostic criterion
.
Diabet Med
2013
;
30
:
825
828
[PubMed]
27.
World Health Organization. Mongolian STEPS Survey on the Prevalence of Noncommunicable Disease and Injury Risk Factors-2009. World Health Organization, Geneva, Switzerland, 2010. Available from http://www.who.int/chp/steps/2009_STEPS_Report_Mongolia.pdf?ua=1. Accessed 31 January 2014
28.
Coppell
KJ
,
Mann
JI
,
Williams
SM
, et al
.
Prevalence of diagnosed and undiagnosed diabetes and prediabetes in New Zealand: findings from the 2008/09 Adult Nutrition Survey
.
N Z Med J
2013
;
126
:
23
42
[PubMed]
29.
Kim
DJ
.
The epidemiology of diabetes in Korea
.
Diabetes Metab J
2011
;
35
:
303
308
[PubMed]
30.
Hwang
J
,
Shon
C
.
Relationship between socioeconomic status and type 2 diabetes: results from Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012
.
BMJ Open
2014
;
4
:
e005710
[PubMed]
31.
Singapore Ministry of Health. Disease Burden. Diabetes prevalence in Singapore [Internet], 2015. Available from https://www.moh.gov.sg/content/moh_web/home/statistics/Health_Facts_Singapore/Disease_Burden.html. Accessed 12 April 2015
32.
Deerochanawong
C
,
Ferrario
A
.
Diabetes management in Thailand: a literature review of the burden, costs, and outcomes
.
Global Health
2013
;
9
:
11
[PubMed]
33.
Aekplakorn
W
,
Chariyalertsak
S
,
Kessomboon
P
, et al.;
Thai National Health Examination Survey IV Study Group
.
Prevalence and management of diabetes and metabolic risk factors in Thai adults: the Thai National Health Examination Survey IV, 2009
.
Diabetes Care
2011
;
34
:
1980
1985
[PubMed]
34.
Quang Binh
T
,
Tran Phuong
P
,
Thi Nhung
B
, et al
.
Prevalence and correlates of hyperglycemia in a rural population, Vietnam: implications from a cross-sectional study
.
BMC Public Health
2012
;
12
:
939
[PubMed]
35.
Zimmet
PZ
.
Kelly West Lecture 1991. Challenges in diabetes epidemiology--from West to the rest
.
Diabetes Care
1992
;
15
:
232
252
[PubMed]
36.
Prior
IA
,
Davidson
F
.
The epidemiology of diabetes in Polynesians and Europeans in New Zealand and the Pacific
.
N Z Med J
1966
;
65
:
375
383
[PubMed]
37.
Zimmet
P
,
Taft
P
,
Guinea
A
,
Guthrie
W
,
Thoma
K
.
The high prevalence of diabetes mellitus on a Central Pacific Island
.
Diabetologia
1977
;
13
:
111
115
[PubMed]
38.
Zimmet
P
,
Dowse
G
,
Finch
C
,
Serjeantson
S
,
King
H
.
The epidemiology and natural history of NIDDM--lessons from the South Pacific
.
Diabetes Metab Rev
1990
;
6
:
91
124
[PubMed]
39.
Collins
VR
,
Dowse
GK
,
Toelupe
PM
, et al
.
Increasing prevalence of NIDDM in the Pacific island population of Western Samoa over a 13-year period
.
Diabetes Care
1994
;
17
:
288
296
[PubMed]
40.
Colagiuri
S
,
Colagiuri
R
,
Na’ati
S
,
Muimuiheata
S
,
Hussain
Z
,
Palu
T
.
The prevalence of diabetes in the kingdom of Tonga
.
Diabetes Care
2002
;
25
:
1378
1383
[PubMed]
41.
Feisul
MI
,
Azmi
S
,
Ed.
National Diabetes Registry Report, Volume 1, 2009-2012 [Internet], 2013. Kuala Lumpur, Ministry of Health Malaysia. Available from http://www.moh.gov.my. Accessed 31 March 2015
[PubMed]
42.
Saeed
KM
.
Prevalence of risk factors for non-communicable diseases in the adult population of urban areas in Kabul City, Afghanistan
.
Cent Asian J Glob Health
2013
;
14
:
386
43.
Akter S, Rahman MM, Abe SK, Sultana P. Prevalence of diabetes and prediabetes and their risk factors among Bangladeshi adults: a nationwide survey. Bull World Health Organ 2014;92:204–213, 213A
44.
Giri
BR
,
Sharma
KP
,
Chapagai
RN
,
Palzom
D
.
Diabetes and hypertension in urban Bhutanese men and women
.
Indian J Community Med
2013
;
38
:
138
143
[PubMed]
45.
Ramachandran
A
,
Snehalatha
C
,
Kapur
A
, et al.;
Diabetes Epidemiology Study Group in India (DESI)
.
High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey
.
Diabetologia
2001
;
44
:
1094
1101
[PubMed]
46.
Anjana
RM
,
Pradeepa
R
,
Deepa
M
, et al.;
ICMR–INDIAB Collaborative Study Group
.
Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study
.
Diabetologia
2011
;
54
:
3022
3027
[PubMed]
47.
Aboobakur
M
,
Latheef
A
,
Mohamed
AJ
, et al
.
Surveillance for non-communicable disease risk factors in Maldives: results from the first STEPS survey in Male
.
Int J Public Health
2010
;
55
:
489
496
[PubMed]
48.
Magliano
DJ
,
Söderberg
S
,
Zimmet
PZ
, et al
.
Explaining the increase of diabetes prevalence and plasma glucose in Mauritius
.
Diabetes Care
2012
;
35
:
87
91
[PubMed]
49.
Sharma
SK
,
Ghimire
A
,
Radhakrishnan
J
, et al
.
Prevalence of hypertension, obesity, diabetes, and metabolic syndrome in Nepal
.
Int J Hypertens
2011
;
2011
:
821971
[PubMed]
50.
Shera
AS
,
Jawad
F
,
Maqsood
A
.
Prevalence of diabetes in Pakistan
.
Diabetes Res Clin Pract
2007
;
76
:
219
222
[PubMed]
51.
Jayawardena R, Ranasinghe P, Byrne NM, Soares MJ, Katulanda P, Hills AP. Prevalence and trends of the diabetes epidemic in South Asia: a systematic review and meta-analysis. BMC Public Health 2012;25;12:380
52.
Anjana
RM
,
Shanthi Rani
CS
,
Deepa
M
, et al
.
Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10-year follow-up of the Chennai Urban Rural Epidemiology Study (CURES)
.
Diabetes Care
2015
;
38
:
1441
1448
[PubMed]
53.
Ramachandran
A
,
Mary
S
,
Yamuna
A
,
Murugesan
N
,
Snehalatha
C
.
High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India
.
Diabetes Care
2008
;
31
:
893
898
[PubMed]
54.
Ma
RC
,
Chan
JC
.
Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States
.
Ann N Y Acad Sci
2013
;
1281
:
64
91
[PubMed]
55.
Hwang
CK
,
Han
PV
,
Zabetian
A
,
Ali
MK
,
Narayan
KM
.
Rural diabetes prevalence quintuples over twenty-five years in low- and middle-income countries: a systematic review and meta-analysis
.
Diabetes Res Clin Pract
2012
;
96
:
271
285
[PubMed]
56.
Lee
JW
,
Brancati
FL
,
Yeh
HC
.
Trends in the prevalence of type 2 diabetes in Asians versus whites: results from the United States National Health Interview Survey, 1997-2008
.
Diabetes Care
2011
;
34
:
353
357
[PubMed]
57.
King
GL
,
McNeely
MJ
,
Thorpe
LE
, et al
.
Understanding and addressing unique needs of diabetes in Asian Americans, native Hawaiians, and Pacific Islanders
.
Diabetes Care
2012
;
35
:
1181
1188
[PubMed]
58.
Karter
AJ
,
Schillinger
D
,
Adams
AS
, et al
.
Elevated rates of diabetes in Pacific Islanders and Asian subgroups: The Diabetes Study of Northern California (DISTANCE)
.
Diabetes Care
2013
;
36
:
574
579
[PubMed]
59.
Kanaya
AM
,
Herrington
D
,
Vittinghoff
E
, et al
.
Understanding the high prevalence of diabetes in U.S. south Asians compared with four racial/ethnic groups: the MASALA and MESA studies
.
Diabetes Care
2014
;
37
:
1621
1628
[PubMed]
60.
Bhopal
R
,
Unwin
N
,
White
M
, et al
.
Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study
.
BMJ
1999
;
319
:
215
220
[PubMed]
61.
Hu
FB
.
Globalization of diabetes: the role of diet, lifestyle, and genes
.
Diabetes Care
2011
;
34
:
1249
1257
[PubMed]
62.
Ma
RC
,
Lin
X
,
Jia
W
.
Causes of type 2 diabetes in China
.
Lancet Diabetes Endocrinol
2014
;
2
:
980
991
[PubMed]
63.
Misra
A
,
Khurana
L
,
Isharwal
S
,
Bhardwaj
S
.
South Asian diets and insulin resistance
.
Br J Nutr
2009
;
101
:
465
473
[PubMed]
64.
Hu
EA
,
Pan
A
,
Malik
V
,
Sun
Q
.
White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review
.
BMJ
2012
;
344
:
e1454
[PubMed]
65.
Mohan
V
,
Radhika
G
,
Sathya
RM
,
Tamil
SR
,
Ganesan
A
,
Sudha
V
.
Dietary carbohydrates, glycaemic load, food groups and newly detected type 2 diabetes among urban Asian Indian population in Chennai, India (Chennai Urban Rural Epidemiology Study 59)
.
Br J Nutr
2009
;
102
:
1498
1506
[PubMed]
66.
Henry
CJ
,
Lightowler
HJ
,
Newens
K
, et al
.
Glycaemic index of common foods tested in the UK and India
.
Br J Nutr
2008
;
99
:
840
845
[PubMed]
67.
Ng
SW
,
Howard
AG
,
Wang
HJ
,
Su
C
,
Zhang
B
.
The physical activity transition among adults in China: 1991-2011
.
Obes Rev
2014
;
15
(
Suppl. 1
):
27
36
[PubMed]
68.
Nyamdorj
R
,
Pitkäniemi
J
,
Tuomilehto
J
, et al.;
DECODA and DECODE Study Groups
.
Ethnic comparison of the association of undiagnosed diabetes with obesity
.
Int J Obes
2010
;
34
:
332
339
[PubMed]
69.
Lear
SA
,
Humphries
KH
,
Kohli
S
,
Chockalingam
A
,
Frohlich
JJ
,
Birmingham
CL
.
Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT)
.
Am J Clin Nutr
2007
;
86
:
353
359
[PubMed]
70.
WHO Expert Consultation.
Appropriate body mass index for Asian populations and its complications for policy and intervention strategies
.
Lancet
2004
;
363
:
157
163
[PubMed]
71.
Huxley
R
,
Barzi
F
,
Lee
CM
, et al.;
Obesity in Asia Collaboration
.
Waist circumference thresholds provide an accurate and widely applicable method for the discrimination of diabetes
.
Diabetes Care
2007
;
30
:
3116
3118
[PubMed]
72.
Cameron AJ, Sicree RA, Zimmet PZ, et al. Cut-points for waist circumference in Europids and South Asians. Obesity (Silver Spring) 2010;18:2039–2046
73.
Hales
CN
,
Barker
DJ
.
Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis
.
Diabetologia
1992
;
35
:
595
601
[PubMed]
74.
Ravelli
AC
,
van der Meulen
JH
,
Michels
RP
, et al
.
Glucose tolerance in adults after prenatal exposure to famine
.
Lancet
1998
;
351
:
173
177
[PubMed]
75.
Li
Y
,
He
Y
,
Qi
L
, et al
.
Exposure to the Chinese famine in early life and the risk of hyperglycemia and type 2 diabetes in adulthood
.
Diabetes
2010
;
59
:
2400
2406
[PubMed]
76.
Yajnik
CS
.
Nutrient-mediated teratogenesis and fuel-mediated teratogenesis: two pathways of intrauterine programming of diabetes
.
Int J Gynaecol Obstet
2009
;
104
(
Suppl. 1
):
S27
S31
[PubMed]
77.
Pettitt
DJ
,
Aleck
KA
,
Baird
HR
,
Carraher
MJ
,
Bennett
PH
,
Knowler
WC
.
Congenital susceptibility to NIDDM. Role of intrauterine environment
.
Diabetes
1988
;
37
:
622
628
[PubMed]
78.
Ma
RC
,
Chan
JC
,
Tam
WH
,
Hanson
MA
,
Gluckman
PD
.
Gestational diabetes, maternal obesity, and the NCD burden
.
Clin Obstet Gynecol
2013
;
56
:
633
641
[PubMed]
79.
Ma
RC
,
Tutino
GE
,
Lillycrop
KA
,
Hanson
MA
,
Tam
WH
.
Maternal diabetes, gestational diabetes and the role of epigenetics in their long term effects on offspring
.
Prog Biophys Mol Biol
2015
;
118
:
55
68
[PubMed]
80.
Guariguata
L
,
Linnenkamp
U
,
Beagley
J
,
Whiting
DR
,
Cho
NH
.
Global estimates of the prevalence of hyperglycaemia in pregnancy
.
Diabetes Res Clin Pract
2014
;
103
:
176
185
[PubMed]
81.
Wong
VW
.
Gestational diabetes mellitus in five ethnic groups: a comparison of their clinical characteristics
.
Diabet Med
2012
;
29
:
366
371
[PubMed]
82.
Zhang
F
,
Dong
L
,
Zhang
CP
, et al
.
Increasing prevalence of gestational diabetes mellitus in Chinese women from 1999 to 2008
.
Diabet Med
2011
;
28
:
652
657
[PubMed]
83.
World Health Organization. Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. World Health Organization, Geneva, Switzerland, 2013. Available from http://apps.who.int/iris/bitstream/10665/85975/1/WHO_NMH_MND_13.2_eng.pdf. Accessed 20 April 2015
84.
Hirst
JE
,
Tran
TS
,
Do
MA
,
Morris
JM
,
Jeffery
HE
.
Consequences of gestational diabetes in an urban hospital in Viet Nam: a prospective cohort study
.
PLoS Med
2012
;
9
:
e1001272
[PubMed]
85.
Hanson
MA
,
Gluckman
PD
,
Ma
RC
,
Matzen
P
,
Biesma
RG
.
Early life opportunities for prevention of diabetes in low and middle income countries
.
BMC Public Health
2012
;
12
:
1025
[PubMed]
86.
Hanson
MA
,
Bardsley
A
,
De-Regil
LM
, et al
.
The International Federation of Gynecology and Obstetrics (FIGO) recommendations on adolescent, preconception, and maternal nutrition: “Think Nutrition First
.”
Int J Gynaecol Obstet
2015
;
131
(
Suppl. 4
):
S213
[PubMed]
87.
Bennett
PH
,
Lee
ET
,
Lu
M
,
Keen
H
,
Fuller
JH
.
Increased urinary albumin excretion and its associations in the WHO Multinational Study of Vascular Disease in Diabetes
.
Diabetologia
2001
;
44
(
Suppl. 2
):
S37
S45
[PubMed]
88.
Kenealy
T
,
Elley
CR
,
Collins
JF
,
Moyes
SA
,
Metcalf
PA
,
Drury
PL
.
Increased prevalence of albuminuria among non-European peoples with type 2 diabetes
.
Nephrol Dial Transplant
2012
;
27
:
1840
1846
[PubMed]
89.
Bhalla
V
,
Zhao
B
,
Azar
KM
, et al
.
Racial/ethnic differences in the prevalence of proteinuric and nonproteinuric diabetic kidney disease
.
Diabetes Care
2013
;
36
:
1215
1221
[PubMed]
90.
Yau
JW
,
Rogers
SL
,
Kawasaki
R
, et al.;
Meta-Analysis for Eye Disease (META-EYE) Study Group
.
Global prevalence and major risk factors of diabetic retinopathy
.
Diabetes Care
2012
;
35
:
556
564
[PubMed]
91.
Tan
ED
,
Davis
WA
,
Davis
TM
.
Changes in characteristics and management of Asian and Anglo-Celts with type 2 diabetes over a 15-year period in an urban Australian community: The Fremantle Diabetes Study
.
J Diabetes.
12 January 2015 [Epub ahead of print]. DOI:
[PubMed]
92.
Kanaya
AM
,
Adler
N
,
Moffet
HH
, et al
.
Heterogeneity of diabetes outcomes among Asians and Pacific Islanders in the US: the Diabetes Study of Northern California (DISTANCE)
.
Diabetes Care
2011
;
34
:
930
937
[PubMed]
93.
Chi
ZS
,
Lee
ET
,
Lu
M
,
Keen
H
,
Bennett
PH
.
Vascular disease prevalence in diabetic patients in China: standardised comparison with the 14 centres in the WHO Multinational Study of Vascular Disease in Diabetes
.
Diabetologia
2001
;
44
(
Suppl. 2
):
S82
S86
[PubMed]
94.
Clarke
PM
,
Glasziou
P
,
Patel
A
, et al.;
ADVANCE Collaborative Group
.
Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis
.
PLoS Med
2010
;
7
:
e1000236
[PubMed]
95.
Yang
X
,
So
WY
,
Kong
AP
, et al
.
Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus
.
Am J Cardiol
2008
;
101
:
596
601
[PubMed]
96.
Chaturvedi
N
,
Abbott
CA
,
Whalley
A
,
Widdows
P
,
Leggetter
SY
,
Boulton
AJ
.
Risk of diabetes-related amputation in South Asians vs. Europeans in the UK
.
Diabet Med
2002
;
19
:
99
104
[PubMed]
97.
Yeung
RO
,
Zhang
Y
,
Luk
A
, et al
.
Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort
.
Lancet Diabetes Endocrinol
2014
;
2
:
935
943
[PubMed]
98.
Chan
JC
,
Lau
ES
,
Luk
AO
, et al
.
Premature mortality and comorbidities in young-onset diabetes: a 7-year prospective analysis
.
Am J Med
2014
;
127
:
616
624
[PubMed]
99.
Ramachandran
A
,
Snehalatha
C
.
Diabetes prevention programs
.
Med Clin North Am
2011
;
95
:
353
372, viii
[PubMed]
100.
Knowler
WC
,
Fowler
SE
,
Hamman
RF
, et al.;
Diabetes Prevention Program Research Group
.
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study
.
Lancet
2009
;
374
:
1677
1686
[PubMed]
101.
Tuomilehto
J
,
Lindström
J
,
Eriksson
JG
, et al.;
Finnish Diabetes Prevention Study Group
.
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
.
N Engl J Med
2001
;
344
:
1343
1350
[PubMed]
102.
Pan
XR
,
Li
GW
,
Hu
YH
, et al
.
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study
.
Diabetes Care
1997
;
20
:
537
544
[PubMed]
103.
Li
G
,
Zhang
P
,
Wang
J
, et al
.
Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study
.
Lancet Diabetes Endocrinol
2014
;
2
:
474
480
[PubMed]
104.
Ramachandran
A
,
Snehalatha
C
,
Mary
S
,
Mukesh
B
,
Bhaskar
AD
,
Vijay
V
;
Indian Diabetes Prevention Programme (IDPP)
.
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)
.
Diabetologia
2006
;
49
:
289
297
[PubMed]
105.
Kosaka
K
,
Noda
M
,
Kuzuya
T
.
Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males
.
Diabetes Res Clin Pract
2005
;
67
:
152
162
[PubMed]
106.
Saito T, Watanabe M, Nishida J, et al.; Zensharen Study for Prevention of Lifestyle Diseases Group. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med 2011;1715:1352–1360
107.
Ramachandran A, Snehalatha C, Shetty SA, Nanditha A. Primary prevention trials in type 2 diabetes. In Global Health Perspectives in Prediabetes and Diabetes Prevention. Bergman M, Ed. Singapore, World Scientific Publication, 2014, p. 49–74
108.
Ramachandran
A
,
Snehalatha
C
,
Ram
J
, et al
.
Effectiveness of mobile phone messaging in prevention of type 2 diabetes by lifestyle modification in men in India: a prospective, parallel-group, randomised controlled trial
.
Lancet Diabetes Endocrinol
2013
;
1
:
191
198
[PubMed]
109.
Chan
JC
,
Zhang
Y
,
Ning
G
.
Diabetes in China: a societal solution for a personal challenge
.
Lancet Diabetes Endocrinol
2014
;
2
:
969
979
[PubMed]
110.
Western Pacific Declaration on Diabetes [Internet], 2001. Available from http://www.wpdd.org/. Accessed 20 April 2015
111.
Ministry of Health Singapore. National Health Survey 2010 [Internet], 2011. Available from http://www.moh.gov.sg/content/moh_web/home/Publications/Reports/2011/national_health_survey2010.html. Accessed 10 April 2015
112.
Phan
TP
,
Alkema
L
,
Tai
ES
, et al
.
Forecasting the burden of type 2 diabetes in Singapore using a demographic epidemiological model of Singapore
.
BMJ Open Diabetes Res Care
2014
;
2
:
e000012
[PubMed]
113.
Ang HS. Singapore's Healthier Hawker Programme. Paper presented at the Culinary Institute of America, 15th Annual Worlds of Flavor Conference, 1–3 November 2012, St. Helena, CA
114.
Chia
SE
,
Chia
A
,
Sng
J
.
A total workplace safety and health service - what are the implications for the employees and employers
?
Ann Acad Med Singapore
2014
;
43
:
475
476
[PubMed]